FTH · Faeth Therapeutics Inc
United States · RS rating 42 · As of 2026-11-03
| Price | 19.65 USD |
|---|---|
| 1-day change | +2.2% |
| RS rating (overall / 1M / 3M / 12M) | 42 / 14 / 31 / 95 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 37 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +97.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +50.9% |
| Market cap (USD) | $459.4M |